Evaluation of Remnant Liver Function Using Primovist-enhanced MRI Before Resection/Ablation of Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

71

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2016

Conditions
Carcinoma, HepatocellularLiver Dysfunction
Interventions
DRUG

Gd-EOB-DTPA

"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."

DRUG

Gd-EOB-DTPA

"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."

PROCEDURE

MRI

"1. Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."

PROCEDURE

MRI

"1. Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.~2. Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."

Trial Locations (4)

Unknown

Cheonnam University Hwasun Hospital, Hwasun-Gun

Asan Medical Center, Seoul

Seoul National University Hospital, Seoul

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Seoul St. Mary's Hospital

OTHER

collaborator

Asan Medical Center

OTHER

collaborator

Chonnam National University Hospital

OTHER

lead

Seoul National University Hospital

OTHER